160,49 €*
Versandkostenfrei per Post / DHL
Aktuell nicht verfügbar
Contemporary monograph on the treatment of breast cancer.-
Gives a comprehensive account of drugs for HER2-positive breast cancer.-
A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology
Includes supplementary material: [...]
Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
Erscheinungsjahr: | 2011 |
---|---|
Fachbereich: | Toxikologie |
Genre: | Medizin |
Rubrik: | Wissenschaften |
Medium: | Buch |
Reihe: | Milestones in Drug Therapy |
Inhalt: |
x
110 S. |
ISBN-13: | 9783034600934 |
ISBN-10: | 3034600933 |
Sprache: | Englisch |
Herstellernummer: | 12548170 |
Ausstattung / Beilage: | HC runder Rücken kaschiert |
Einband: | Gebunden |
Redaktion: |
Sibilia, Maria
Grunt, Thomas W. Bartsch, Rupert Zielinski, Christoph C. |
Herausgeber: | Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al |
Hersteller: |
Springer Basel
Springer Basel AG Milestones in Drug Therapy |
Maße: | 241 x 160 x 13 mm |
Von/Mit: | Maria Sibilia (u. a.) |
Erscheinungsdatum: | 07.01.2011 |
Gewicht: | 0,376 kg |
Contemporary monograph on the treatment of breast cancer.-
Gives a comprehensive account of drugs for HER2-positive breast cancer.-
A valuable source of information for researchers and clinicians from the fields of oncology and pharmacology
Includes supplementary material: [...]
Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
Erscheinungsjahr: | 2011 |
---|---|
Fachbereich: | Toxikologie |
Genre: | Medizin |
Rubrik: | Wissenschaften |
Medium: | Buch |
Reihe: | Milestones in Drug Therapy |
Inhalt: |
x
110 S. |
ISBN-13: | 9783034600934 |
ISBN-10: | 3034600933 |
Sprache: | Englisch |
Herstellernummer: | 12548170 |
Ausstattung / Beilage: | HC runder Rücken kaschiert |
Einband: | Gebunden |
Redaktion: |
Sibilia, Maria
Grunt, Thomas W. Bartsch, Rupert Zielinski, Christoph C. |
Herausgeber: | Maria Sibilia/Christoph C Zielinski/Rupert Bartsch et al |
Hersteller: |
Springer Basel
Springer Basel AG Milestones in Drug Therapy |
Maße: | 241 x 160 x 13 mm |
Von/Mit: | Maria Sibilia (u. a.) |
Erscheinungsdatum: | 07.01.2011 |
Gewicht: | 0,376 kg |